Samsung Biologics Co Ltd (207940) — Cash Flow Reinvestment Rate
Samsung Biologics Co Ltd (207940) has a Cash Flow Reinvestment Rate of 1.44x as of June 2026, reinvesting ₩898.75 Billion (capex ₩99.08 Billion plus investments ₩-799.67 Billion) from operating cash flow of ₩624.80 Billion. See Samsung Biologics Co Ltd (207940) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Samsung Biologics Co Ltd Cash Flow Reinvestment Rate (2017–2025)
Historical reinvestment intensity for Samsung Biologics Co Ltd across 8 annual periods. For the full cash flow conversion analysis, see Samsung Biologics Co Ltd cash conversion from operations.
Annual Cash Flow Reinvestment Rate for Samsung Biologics Co Ltd (2017–2025)
Year-by-year capital reinvestment analysis for Samsung Biologics Co Ltd. See 207940 free cash flow debt coverage to measure the company's free cash flow as a share of total liabilities.
| Year | Reinvestment Rate | Total Reinvested (KRW) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 0.84x | ₩1.88 Trillion | ₩2.25 Trillion | ₩1.48 Trillion | ▼ -34.6% |
| 2024 | 1.28x | ₩2.12 Trillion | ₩1.66 Trillion | ₩1.38 Trillion | ▼ -20.2% |
| 2023 | 1.60x | ₩2.67 Trillion | ₩1.67 Trillion | ₩1.11 Trillion | ▼ -22.5% |
| 2022 | 2.07x | ₩1.97 Trillion | ₩953.05 Billion | ₩956.84 Billion | ▲ +2.4% |
| 2021 | 2.02x | ₩918.63 Billion | ₩454.60 Billion | ₩406.25 Billion | ▼ -0.4% |
| 2020 | 2.03x | ₩409.83 Billion | ₩202.09 Billion | ₩139.66 Billion | ▼ -97.2% |
| 2019 | 72.36x | ₩734.74 Billion | ₩10.15 Billion | ₩192.84 Billion | ▲ +757.6% |
| 2017 | 8.44x | ₩1.26 Trillion | ₩149.82 Billion | ₩494.12 Billion | — |